High-risk T2D: canagliflozin delays need for insulin initiation in CANVAS

  • Matthews DR & al.
  • Diabetes Obes Metab
  • 20 Jul 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Canagliflozin delayed the time to insulin therapy and the need for initiation of other antihyperglycaemic agents (AHAs) compared with placebo over a 5-year period in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.

Why this matters

  • Lower use of insulin and other AHAs associated with canagliflozin may represent reduced utilisation of health services, reduced healthcare costs, better adherence and improved patient satisfaction.

Study design

  • Post hoc analysis of CANVAS Program: 2 randomised controlled trials among 10,142 patients with T2D and high CVD risk.
  • Randomisation: canagliflozin vs placebo.
  • Main outcome: initiation of insulin and other AHAs.
  • Funding: Janssen Research & Development, LLC.

Key results

  • At 1 year, fewer participants in the canagliflozin vs placebo group initiated any AHA (7% vs 16%), insulin (3% vs 9%) or any non-insulin AHA (5% vs 12%; P<.001 for all>
  • Overall AHA initiation increased over time but was consistently lower with canagliflozin vs placebo:
    • At 3 years (any AHA: 19% vs 32%; insulin: 9% vs 21%; or non-insulin AHA: 15% vs 26%); and
    • At 5 years (any AHA: 28% vs 43%; insulin: 14% vs 30%; or non-insulin AHA: 23% vs 36%).
  • Patients treated with canagliflozin vs placebo were less likely to initiate:
    • any AHA (HR, 0.47; 95% CI, 0.43-0.51);
    • insulin (HR, 0.37; 95% CI, 0.31-0.43); and
    • any non-insulin AHA (HR, 0.50; 95% CI, 0.45-0.55; P for all <.001>
  • The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was >2 years.
  • Canagliflozin vs placebo delayed the time for initiation of other AHAs, including metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sulphonylureas (P<.001 for each>

Limitations

  • Post hoc analysis.